{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:42:48Z","timestamp":1787506968866,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,9,16]],"date-time":"2007-09-16T00:00:00Z","timestamp":1189900800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s00120-007-1553-9","type":"journal-article","created":{"date-parts":[[2007,9,14]],"date-time":"2007-09-14T09:39:13Z","timestamp":1189762753000},"page":"1364-1370","source":"Crossref","is-referenced-by-count":4,"title":["Das \u201eProstate Cancer Prevention Trial\u201c (PCPT)","The Prostate Cancer Prevention Trial (PCPT)"],"prefix":"10.1007","volume":"46","author":[{"given":"B.J.","family":"Schmitz-Dr\u00e4ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bismarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"D\u00f6rsam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"L\u00fcmmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,16]]},"reference":[{"key":"1553_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215\u2013224","journal-title":"N Engl J Med"},{"key":"1553_CR2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","volume":"350","author":"Thompson","year":"2004","unstructured":"Thompson IM, Pauler DK, Goodman PJ et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0\u00a0ng per milliliter. N Engl J Med 350: 2239\u20132246","journal-title":"N Engl J Med"},{"key":"1553_CR3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/01.ju.0000139320.78673.2a","volume":"172","author":"Andriole","year":"2004","unstructured":"Andriole G, Bostwick D, Brawley O et al. REDUCE Study Group (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172: 1314\u20131317","journal-title":"J Urol"},{"key":"1553_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMe038109","volume":"349","author":"Scardino","year":"2003","unstructured":"Scardino P (2003) The prevention of prostate cancer \u2013 the dilemma continues. N Engl J Med 349: 297\u2013299","journal-title":"N Engl J Med"},{"key":"1553_CR5","unstructured":"Ian Thompson (2006) The prostate cancer prevention trial \u2013 update. Prostate Cancer Symp, San Francisco, Feb 24\u201326, 2006"},{"key":"1553_CR6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-5347(05)00236-3","volume":"175","author":"Kulkarni","year":"2006","unstructured":"Kulkarni GS, Al-Azab R, Lockwood G et al. (2006) Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175: 505\u2013509","journal-title":"J Urol"},{"key":"1553_CR7","first-page":"154","volume":"78","author":"Ankerst","year":"2006","unstructured":"Ankerst DP, Thompson IM (2006) New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl 78: 154\u2013156","journal-title":"Arch Ital Urol Androl"},{"key":"1553_CR8","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1200\/JCO.2005.08.159","volume":"23","author":"Klein","year":"2005","unstructured":"Klein EA, Tangen CM, Goodman PJ et al. (2005) Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. J Clin Oncol 23: 7388\u20137390","journal-title":"J Clin Oncol"},{"key":"1553_CR9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.eursup.2006.05.001","volume":"5","author":"Teillac","year":"2006","unstructured":"Teillac P, Abrahamsson PA (2006) The prostate cancer prevention trial and its implications for clinical practise: a European consensus. Eur Urol 5(Suppl): 640\u2013646","journal-title":"Eur Urol"},{"key":"1553_CR10","first-page":"47","volume":"4","author":"Stellungnahme","year":"2006","unstructured":"Stellungnahme des Arbeitskreises Pr\u00e4vention, Umwelt und Komplement\u00e4rmedizin (PUK) und des Arbeitskreises Onkologie (AKO) der Akademie der Deutschen Urologen (2006) Chemopr\u00e4vention des Prostatakarzinoms \u2013 eine Neubewertung. Blickpunkt. Der Mann 4: 47","journal-title":"Der Mann"},{"key":"1553_CR11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1056\/NEJM200412233512622","volume":"351","author":"Imamov","year":"2004","unstructured":"Imamov O, Lopatkin NA, Gustafsson JA (2004) Estrogen receptor beta in prostate cancer. N Engl J Med 351: 2773\u20132774","journal-title":"N Engl J Med"},{"key":"1553_CR12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djj307","volume":"98","author":"Thompson","year":"2006","unstructured":"Thompson IM, Chi C, Goodman P et al. (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98: 1128\u20131133","journal-title":"J Natl Cancer Inst"},{"key":"1553_CR13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3816\/CGC.2004.n.004","volume":"2","author":"Bostwick","year":"2004","unstructured":"Bostwick DG, Qian J, Civantos F et al. (2004) Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2: 228\u2013235","journal-title":"Clin Prostate Cancer"},{"key":"1553_CR14","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1097\/01.ju.0000181216.71605.38","volume":"174","author":"Andriole","year":"2005","unstructured":"Andriole G, Bostwick D, Civantos F et al. (2005) The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol 174: 2098\u20132104","journal-title":"J Urol"},{"key":"1553_CR15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.eururo.2003.11.024","volume":"45","author":"Eskicorapci","year":"2004","unstructured":"Eskicorapci SY, Baydar DE, Akbal C et al. (2004) An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 45: 444\u2013449","journal-title":"Eur Urol"},{"key":"1553_CR16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.ju.0000112763.74119.d4","volume":"171","author":"Singh","year":"2004","unstructured":"Singh H, Canto EI, Shariat SF et al. (2004) Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171: 1089\u20131092","journal-title":"J Urol"},{"key":"1553_CR17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.juro.2007.03.012","volume":"178","author":"Thompson","year":"2007","unstructured":"Thompson IM, Lucia MS, Redman MW et al. (2007) Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 178: 107\u2013109","journal-title":"J Urol"},{"key":"1553_CR18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1569-9056(07)60604-6","volume":"6","author":"Schr\u00f6der","year":"2007","unstructured":"Schr\u00f6der FH, Roobol MJ, Van Leenders GJLH, Bangma CH (2007) How to screen for prostate cancer (PC) in men with low PSA (<3.0\u00a0ng\/ml) \u2013 do we have to find all cancers? Eur Urol 6(Suppl): 174","journal-title":"Eur Urol"},{"key":"1553_CR19","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371\u20131388","journal-title":"J Natl Cancer Inst"},{"key":"1553_CR20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1464-410X.2003.04486.x","volume":"92","author":"Marberger","year":"2003","unstructured":"Marberger M, Adolfsson J, Borkowski A et al. (2003) The clinical implications of the prostate cancer prevention trial. BJU Int 92: 667\u2013671","journal-title":"BJU Int"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-007-1553-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1553-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T06:58:48Z","timestamp":1558594728000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-007-1553-9"}},"subtitle":["Die Bedeutung f\u00fcr den klinischen Alltag","Relevance for clinical practice"],"short-title":[],"issued":{"date-parts":[[2007,9,16]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s00120-007-1553-9","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,16]]}}}